ArticleBMC infectious diseases2019
Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil.
Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Accuracy of rapid point-of-care serological tests for leprosy diagnosis: a systematic review and meta-analysis.Memorias do Instituto Oswaldo Cruz · 2022Pooled it
- Implementation of ML Flow for leprosy contacts in Brazil: Opportunities, pitfalls, and safeguards.PLoS neglected tropical diseases · 2026Review
- Biosensor-Based Platforms for the Detection and Screening ofACS infectious diseases · 2026Review
- Public Health Response to Imported Hansen's Disease Cases and Contact Investigation Findings in the Chungcheong Region, 2024-2025.Public health weekly report · 2026Article
- Decoding leprosy: immune response, clinical manifestations and emerging diagnostic approaches.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2025Review
- Serum anti-lipid antibodies in patients affected by leprosy in a high-burden municipality in Brazil: a cross-sectional study.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- A cost-effectiveness analysis of a novel algorithm to sequentially diagnose leprosy based on manufactured tests under the SUS perspective.Cadernos de saude publica · 2024Article
- Challenges and advances in serological and molecular tests to aid leprosy diagnosis.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- HSP60 mimetic peptides from Mycobacterium leprae as new antigens for immunodiagnosis of Leprosy.AMB Express · 2023Article
- Profile of the leprosy endemic in the district of Murrupula, Nampula, Mozambique: A population-based study.Revista da Sociedade Brasileira de Medicina Tropical · 2023Article
- Can anti-PGL-I antibody isotypes differentiate leprosy contacts and leprosy patients?Pathogens and global health · 2022Article
- ELISA Test Based on the Phenolic Glycolipid-I (PGL-I) ofPathogens (Basel, Switzerland) · 2022Article
- Leprosy: A Review of Epidemiology, Clinical Diagnosis, and Management.Journal of tropical medicine · 2022Review
- Anti-Leishmania IgG is a marker of disseminated leishmaniasis caused by Leishmania braziliensis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- Insights intoProteomes · 2021Review
- Leprosy surveillance study in a highly endemic Brazilian area using leprosy specific serologic tests and IFNγ whole blood assay.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Extensor plaques with associated arthritis and neuropathy.JAAD case reports · 2020Article
- [Leprosy in Amazonas-impressions of the National Leprosy Program].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2020Review
- Recombinant polypeptide of Mycobacterium leprae as a potential tool for serological detection of leprosy.AMB Express · 2019Article
- Application of new host biomarker profiles in quantitative point-of-care tests facilitates leprosy diagnosis in the field.EBioMedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly detection of leprosy and multidrug therapy are crucial to achieve zero transmission and zero grade II incapacities goals of World Health Organization. Leprosy is difficult to diagnose because clinical forms vary and there are no gold standard methods to guide clinicians. The serological rapid tests aid the clinical diagnosis and are available for field use. They are easy to perform, do not require special equipment or refrigeration and are cheaper than the molecular tests.
methodsWe evaluated the performance of two rapid serological tests (PGL1 and NDO-LID) in the discrimination of leprosy cases from healthy individuals at the Alfredo da Matta Foundation, a reference center for the disease in Manaus, Amazonas, Brazil. PGL1 and NDO-LID rapid tests are capable of detecting specific antibodies of M. leprae, IgM and IgM/IgG, respectively. A total of 530 healthy subjects and 171 patients (50 with paucibacillary and 121 multibacillary leprosy) were included in the study.
resultsAmong the paucibacillary leprosy patients, the sensitivity was 34.0 and 32.0% for the NDO-LID and PGL1, respectively. In multibacillary leprosy patients, the NDO-LID sensitivity was 73.6% and the PGL1 was 81.0%. Serological tests demonstrated specificities of 75.9% for PGL-1 and 81.7% for NDO-LID. The positive predictive value (PPV), negative predictive value (NPV) and accuracy in multibacillary patients were 47.9, 93.1, and 80.2% respectively for the NDO-LID, and 43.4, 94.6 76.8% for PGL1.
conclusionsThe tests showed limited capacity in the diagnosis of the disease, however, the high negative predictive value of the tests indicates a greater chance of true negatives in this group favoring exclusion of leprosy. This characteristic of the ML flow test is important in aiding clinical Diagnosis, especially in a region endemic to the disease and with other confounding skin conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.